id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-281561-r10y2sgb	Tiwari, Nidhi	Novel β-Coronavirus (SARS-CoV-2): Current and Future Aspects of Pharmacological Treatments	2020-08-27		.txt	text/plain	6877	384	45	Another invitro study reported that Ribavirin, analogue of guanosine nucleotide having wide spectrum of antiviral activity, used along with LPV/RTV to treat SARS-COV-2 viral infection in china (ChiCTR2000029387) . reported remdesivir shows possible efficacy better as compared to placebo group in hospitalized patients for the treatment of SARS-CoV-2 virus. The effectiveness and safety concern of darunavir/cobicistat combination is being evaluated under development of clinical trials phase 3 by enrolling 30 COVID-19 patients and estimated completion of study on December 31, 2020. Recently, retrospective cohort study showed high dose of anakinra (5 mg/kg, BD,iv) produces beneficial and efficacious effects in 72% Covid-19 infected patients associated with ARDS (Cavalli et al., 2020) . Based on case study of patients with SARS-CoV2 infection and also confirmed severe pneumonia and ARDS treated with i.v. infusion of eculizumab along with anticoagulant therapy (Enoxaparin 4000 IU/day s.c), antiviral therapy (LPV 800 mg/day + RTV 200 mg/day), hydroxychloroquine 400 mg/day, ceftriaxone 2 g/day IV, vitamin C 6 g/day for 4 days.	./cache/cord-281561-r10y2sgb.txt	./txt/cord-281561-r10y2sgb.txt